Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 80,600 shares, an increase of 258.2% from the December 31st total of 22,500 shares. Currently, 4.6% of the company’s shares are short sold. Based on an average trading volume of 358,600 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned approximately 1.17% of Avenue Therapeutics at the end of the most recent reporting period. 17.34% of the stock is owned by institutional investors and hedge funds.

Avenue Therapeutics Trading Down 1.5 %

NASDAQ:ATXI traded down $0.02 during midday trading on Thursday, hitting $1.32. 177,001 shares of the company traded hands, compared to its average volume of 1,158,499. The firm’s fifty day moving average is $1.86 and its 200-day moving average is $2.29. The firm has a market capitalization of $2.71 million, a P/E ratio of 0.07 and a beta of -0.27. Avenue Therapeutics has a 12-month low of $1.26 and a 12-month high of $15.00.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.